251 related articles for article (PubMed ID: 15213312)
1. Azithromycin for improving pulmonary function in cystic fibrosis.
Carr RR; Nahata MC
Ann Pharmacother; 2004 Sep; 38(9):1520-4. PubMed ID: 15213312
[TBL] [Abstract][Full Text] [Related]
2. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
[TBL] [Abstract][Full Text] [Related]
3. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
Pirzada OM; McGaw J; Taylor CJ; Everard ML
J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
Wilms EB; Touw DJ; Heijerman HG
Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
[TBL] [Abstract][Full Text] [Related]
6. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
[TBL] [Abstract][Full Text] [Related]
7. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
[TBL] [Abstract][Full Text] [Related]
8. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
Hansen CR; Pressler T; Koch C; Høiby N
J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
[TBL] [Abstract][Full Text] [Related]
9. Macrolide antibiotics for cystic fibrosis.
Southern KW; Barker PM; Solis-Moya A; Patel L
Cochrane Database Syst Rev; 2011 Dec; (12):CD002203. PubMed ID: 22161368
[TBL] [Abstract][Full Text] [Related]
10. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
Nguyen D; Emond MJ; Mayer-Hamblett N; Saiman L; Marshall BC; Burns JL
Pediatr Pulmonol; 2007 Jun; 42(6):533-41. PubMed ID: 17469154
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC;
Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785
[TBL] [Abstract][Full Text] [Related]
12. Exploring the mechanisms of macrolides in cystic fibrosis.
Equi AC; Davies JC; Painter H; Hyde S; Bush A; Geddes DM; Alton EW
Respir Med; 2006 Apr; 100(4):687-97. PubMed ID: 16185859
[TBL] [Abstract][Full Text] [Related]
13. [Macrolides, Pseudomonas aeruginosa and cystic fibrosis].
Guillot M; Amiour M; El Hachem C; Harchaoui S; Ribault V; Paris C
Arch Pediatr; 2006 Oct; 13 Suppl 1():S48-50. PubMed ID: 17370396
[TBL] [Abstract][Full Text] [Related]
14. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
Hansen CR; Pressler T; Hoiby N; Johansen HK
J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
[TBL] [Abstract][Full Text] [Related]
15. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
16. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.
Saiman L; Mayer-Hamblett N; Anstead M; Lands LC; Kloster M; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
Pediatr Pulmonol; 2012 Jul; 47(7):641-8. PubMed ID: 22684984
[TBL] [Abstract][Full Text] [Related]
17. [Effects of azithromycin on the virulence of Pseudomonas aeruginosa].
Reinert P
Pathol Biol (Paris); 1995 Jun; 43(6):551-3. PubMed ID: 8539081
[TBL] [Abstract][Full Text] [Related]
18. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Assael BM
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
[TBL] [Abstract][Full Text] [Related]
19. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.
Phaff SJ; Tiddens HA; Verbrugh HA; Ott A
J Antimicrob Chemother; 2006 Apr; 57(4):741-6. PubMed ID: 16469851
[TBL] [Abstract][Full Text] [Related]
20. The use of macrolide antibiotics in patients with cystic fibrosis.
Saiman L
Curr Opin Pulm Med; 2004 Nov; 10(6):515-23. PubMed ID: 15510060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
